Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Percheron Therapeutics ( (AU:PER) ) has provided an update.
Percheron Therapeutics has appointed Eugene Kennedy as Chief Medical Officer and Valentina Dubljevic as Chief Technology Officer to advance its lead program, HMBD-002, into a phase II clinical trial expected to begin recruitment in CY2026. These strategic appointments are aimed at strengthening the company’s capabilities in clinical development and manufacturing, potentially enhancing its position in the biotechnology industry and offering promising therapeutic options for cancer treatment.
The most recent analyst rating on (AU:PER) stock is a Hold with a A$0.01 price target. To see the full list of analyst forecasts on Percheron Therapeutics stock, see the AU:PER Stock Forecast page.
More about Percheron Therapeutics
Percheron Therapeutics Limited is a publicly listed biotechnology company focused on developing and commercializing novel therapies for oncology and rare diseases. The company’s lead program, HMBD-002, is a monoclonal antibody targeting the immune checkpoint regulator, VISTA, and has completed a phase I clinical trial showing it to be generally safe and well-tolerated.
Average Trading Volume: 4,290,184
Technical Sentiment Signal: Sell
Current Market Cap: A$10.87M
Learn more about PER stock on TipRanks’ Stock Analysis page.